Adamis Pharmaceuticals Corporation (ADMP) Social Stream



Adamis Pharmaceuticals Corporation (ADMP): $0.78

0.01 (+0.86%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

D

ADAMIS PHARMACEUTICALS CORP (ADMP) Price Targets From Analysts

Use the tables below to see what analysts covering ADAMIS PHARMACEUTICALS CORP think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
NA 1 $NA $NA $NA $0.775 NA%

Price Target Last Issued NA NA, NA

ADMP Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
3 0 0 2 0 0 2

The Trend in the Broker Recommendations


ADMP's average broker recommendation rating improved by 0 over the prior 122 days.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • To contextualize these metrics, consider that out of all US stocks, ADAMIS PHARMACEUTICALS CORP's number of analysts covering the stock is higher than 3.07% of them.
  • To contextualize these metrics, consider that out of stocks in the micro market cap category, ADAMIS PHARMACEUTICALS CORP's variance in analysts' estimates is lower than nearly 100% of them.
  • In the context of stocks in the micro market cap category, ADAMIS PHARMACEUTICALS CORP's average analyst price target is higher than practically none of them.
  • ADMP has a greater upside potential (average analyst target price relative to current price) than practically none of stocks in the micro market cap category.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to ADAMIS PHARMACEUTICALS CORP are PRPH, SNGX, and LTRN.

Make investment decisions regarding ADMP using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!